title: PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
abstract: OBJECTIVE
  To study the prognostic value of the prostate-specific antigen (PSA) response and its relationship with other initial prognostic factors during the treatment of advanced prostatic carcinoma with total androgen blockade.
  
  
  METHODS
  Five hundred forty-six patients with advanced loco-regional (M0) or distant metastatic (M1) prostatic carcinoma treated with flutamide combined with either orchiectomy or LHRH analogues were included in this analysis. Initial patients characteristics and the PSA response were evaluated in relation to progression-free survival using a univariate and multivariate (Cox regression) analysis.
  
  
  RESULTS
  The following prognostic factors were indicative of a decrease in progression-free survival: the absence of PSA normalization (< 4 ng/ml) after 3 or 6 months, M1 stage, high G grade, ECOG performance status > 1, presence of pain and absence of dysuria. In M1 patients the combination of PSA normalization after 3 or 6 months with initial G grade and ECOG performance status had the strongest predictive value.
  
  
  CONCLUSIONS
  This study demonstrates that PSA normalization after 3 or 6 months along with initial tumor stage, grade and health status of the patient are the most important prognostic factors related to progression-free survival in the hormonal treatment of advanced prostatic carcinoma.
authors.affiliation: Department of Urology, University Hospital of Ghent, Belgium.
authors.forename: W
authors.initials: W
authors.lastname: Oosterlinck
authors.forename: J
authors.initials: J
authors.lastname: Mattelaer
authors.forename: J
authors.initials: J
authors.lastname: Casselman
authors.forename: R
authors.initials: R
authors.lastname: Van Velthoven
authors.forename: M P
authors.initials: MP
authors.lastname: Derde
authors.forename: L
authors.initials: L
authors.lastname: Kaufman
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001530:Belgium; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary / Q000601:surgery; D018450:Disease Progression; D018572:Disease-Free Survival; D005485:Flutamide / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006304:Health Status; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D009919:Orchiectomy; D010146:Pain / Q000503:physiopathology; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012044:Regression Analysis; D012449:Safety; D015996:Survival Rate; D014555:Urination Disorders / Q000503:physiopathology
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D005485:Flutamide; D017430:Prostate-Specific Antigen